Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.

Varadi, Melinda; Nagy, Nikolett; Reis, Henning; Hadaschik, Boris; Niedworok, Christian; Modos, Orsolya; Szendroi, Attila; Ablat, Jason; Black, Peter C; Keresztes, David; Csizmarik, Anita; Olah, Csilla; Gaisa, Nadine T; Kiss, Andras; Timar, Jozsef; Toth, Erika; Csernak, Erzsebet; Gerstner, Arpad; Mittal, Vinay; Karkampouna, Sofia; ... (2023). Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas. Cancer medicine, 12(7), pp. 9041-9054. Wiley 10.1002/cam4.5639

Preview

Text Cancer_Medicine_-_2023_-_Varadi_-_Clinical_sequencing_identifies_potential_actionable_alterations_in_a_high_rate_of_urachal.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (4MB) | Preview

OBJECTIVE

Administration of targeted therapies provides a promising treatment strategy for urachal adenocarcinoma (UrC) or primary bladder adenocarcinoma (PBAC); however, the selection of appropriate drugs remains difficult. Here, we aimed to establish a routine compatible methodological pipeline for the identification of the most important therapeutic targets and potentially effective drugs for UrC and PBAC.

METHODS

Next-generation sequencing, using a 161 cancer driver gene panel, was performed on 41 UrC and 13 PBAC samples. Clinically relevant alterations were filtered, and therapeutic interpretation was performed by in silico evaluation of drug-gene interactions.

RESULTS

After data processing, 45/54 samples passed the quality control. Sequencing analysis revealed 191 pathogenic mutations in 68 genes. The most frequent gain-of-function mutations in UrC were found in KRAS (33%), and MYC (15%), while in PBAC KRAS (25%), MYC (25%), FLT3 (17%) and TERT (17%) were recurrently affected. The most frequently affected pathways were the cell cycle regulation, and the DNA damage control pathway. Actionable mutations with at least one available approved drug were identified in 31/33 (94%) UrC and 8/12 (67%) PBAC patients.

CONCLUSIONS

In this study, we developed a data-processing pipeline for the detection and therapeutic interpretation of genetic alterations in two rare cancers. Our analyses revealed actionable mutations in a high rate of cases, suggesting that this approach is a potentially feasible strategy for both UrC and PBAC treatments.

Interest & Impact

Downloads

53 since deposited on 27 Jan 2023
53 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item